Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
21.15 USD | +0.76% | -1.74% | -11.57% |
14/05 | Stephens Initiates Exelixis With Equalweight Rating, $23 Price Target | MT |
10/05 | Exelixis Files Patent Complaint Against Cipla's Cancer Treatment | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.57% | 611.42Cr | |
+7.33% | 11TCr | |
+11.20% | 11TCr | |
-12.46% | 2.22TCr | |
+0.44% | 2.13TCr | |
-4.18% | 1.9TCr | |
-37.85% | 1.85TCr | |
-8.56% | 1.68TCr | |
+37.58% | 1.25TCr | |
-24.25% | 808.97Cr |
- Stock Market
- Equities
- EXEL Stock
- News Exelixis, Inc.
- RBC Trims Exelixis' Price Target to $27 From $28, Outperform Rating Kept